Performance differences among commercially available antigen rapid tests for COVID-19 in Brazil
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2022 |
| Outros Autores: | , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da UFMG |
| Texto Completo: | https://doi.org/10.1371/journal. pone.0269997 http://hdl.handle.net/1843/61859 https://orcid.org/0000-0003-0538-7403 |
Resumo: | CAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior |
| id |
UFMG_f0b4da48986cc6ca7982e9a522e53d6a |
|---|---|
| oai_identifier_str |
oai:repositorio.ufmg.br:1843/61859 |
| network_acronym_str |
UFMG |
| network_name_str |
Repositório Institucional da UFMG |
| repository_id_str |
|
| spelling |
2023-12-07T22:51:50Z2023-12-07T22:51:50Z2022-06-16176113https://doi.org/10.1371/journal. pone.02699971932-6203http://hdl.handle.net/1843/61859https://orcid.org/0000-0003-0538-7403CAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível SuperiorOutra AgênciaA rapid and accurate diagnosis is a crucial strategy for containing the coronavirus disease (COVID-19) pandemic. Considering the obstacles to upscaling the use of RT–qPCR, rapid tests based on antigen detection (Ag-RDT) have become an alternative to enhance mass testing, reducing the time for a prompt diagnosis and virus spreading. However, the performances of several commercially available Ag-RDTs have not yet been evaluated in several countries. Here, we evaluate the performance of eight Ag-RDTs available in Brazil to diagnose COVID-19. Patients admitted to tertiary hospitals with moderate or mild COVID-19 symptoms and presenting risk factors for severe disease were included. The tests were performed using a masked protocol, strictly following the manufacturer’s recommendations and were compared with RT–qPCR. The overall sensitivity of the tests ranged from 9.8 to 81.1%, and specificity greater than 83% was observed for all the evaluated tests. Overall, slight or fair agreement was observed between Ag-RDTs and RT–PCR, except for the Ag-RDT COVID-19 (Acro Biotech), in which moderate agreement was observed. Lower sensitivity of Ag-RDTs was observed for patients with cycle threshold > 25, indicating that the sensitivity was directly affected by viral load, whereas the effect of the disease duration was unclear. Despite the lower sensitivity of Ag-RDTs compared with RT–qPCR, its easy fulfillment and promptness still justify its use, even at hospital admission. However, the main advantage of Ag-RDTs seems to be the possibility of increasing access to the diagnosis of COVID-19 in patients with a high viral load, allowing immediate clinical management and reduction of infectivity and community transmission.engUniversidade Federal de Minas GeraisUFMGBrasilHCL - HOSPITAL DAS CLINICASMEDICINA - FACULDADE DE MEDICINAPlos OneTestes de Diagnóstico RápidoTeste para COVID-19BrasilAntigen rapid testsCOVID-19BrazilPerformance differences among commercially available antigen rapid tests for COVID-19 in Brazilinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0269997Mariana Lourenço FreireDaniel Moreira AvelarGlaucia Fernandes CotaLindicy Leidicy AlvesCarolina Senra de SouzaJuliana Wilke SalibaVerônica FariaMariana Junqueira PedrasNara de Oliveira CarvalhoGláucia Queiroz AndradeAna Rabelloapplication/pdfinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFMGinstname:Universidade Federal de Minas Gerais (UFMG)instacron:UFMGLICENSELicense.txtLicense.txttext/plain; charset=utf-82042https://repositorio.ufmg.br/bitstream/1843/61859/1/License.txtfa505098d172de0bc8864fc1287ffe22MD51ORIGINALPerformance differences among commercially available antigen rapid tests for COVID-19 in Brazil.pdfPerformance differences among commercially available antigen rapid tests for COVID-19 in Brazil.pdfapplication/pdf5774893https://repositorio.ufmg.br/bitstream/1843/61859/2/Performance%20differences%20among%20commercially%20available%20antigen%20rapid%20tests%20for%20COVID-19%20in%20Brazil.pdfc5748642ac5f83cf6b04b0755c49b2abMD521843/618592023-12-07 19:51:50.84oai:repositorio.ufmg.br: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Repositório de PublicaçõesPUBhttps://repositorio.ufmg.br/oaiopendoar:2023-12-07T22:51:50Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)false |
| dc.title.pt_BR.fl_str_mv |
Performance differences among commercially available antigen rapid tests for COVID-19 in Brazil |
| title |
Performance differences among commercially available antigen rapid tests for COVID-19 in Brazil |
| spellingShingle |
Performance differences among commercially available antigen rapid tests for COVID-19 in Brazil Mariana Lourenço Freire Antigen rapid tests COVID-19 Brazil Testes de Diagnóstico Rápido Teste para COVID-19 Brasil |
| title_short |
Performance differences among commercially available antigen rapid tests for COVID-19 in Brazil |
| title_full |
Performance differences among commercially available antigen rapid tests for COVID-19 in Brazil |
| title_fullStr |
Performance differences among commercially available antigen rapid tests for COVID-19 in Brazil |
| title_full_unstemmed |
Performance differences among commercially available antigen rapid tests for COVID-19 in Brazil |
| title_sort |
Performance differences among commercially available antigen rapid tests for COVID-19 in Brazil |
| author |
Mariana Lourenço Freire |
| author_facet |
Mariana Lourenço Freire Daniel Moreira Avelar Glaucia Fernandes Cota Lindicy Leidicy Alves Carolina Senra de Souza Juliana Wilke Saliba Verônica Faria Mariana Junqueira Pedras Nara de Oliveira Carvalho Gláucia Queiroz Andrade Ana Rabello |
| author_role |
author |
| author2 |
Daniel Moreira Avelar Glaucia Fernandes Cota Lindicy Leidicy Alves Carolina Senra de Souza Juliana Wilke Saliba Verônica Faria Mariana Junqueira Pedras Nara de Oliveira Carvalho Gláucia Queiroz Andrade Ana Rabello |
| author2_role |
author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Mariana Lourenço Freire Daniel Moreira Avelar Glaucia Fernandes Cota Lindicy Leidicy Alves Carolina Senra de Souza Juliana Wilke Saliba Verônica Faria Mariana Junqueira Pedras Nara de Oliveira Carvalho Gláucia Queiroz Andrade Ana Rabello |
| dc.subject.por.fl_str_mv |
Antigen rapid tests COVID-19 Brazil |
| topic |
Antigen rapid tests COVID-19 Brazil Testes de Diagnóstico Rápido Teste para COVID-19 Brasil |
| dc.subject.other.pt_BR.fl_str_mv |
Testes de Diagnóstico Rápido Teste para COVID-19 Brasil |
| description |
CAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior |
| publishDate |
2022 |
| dc.date.issued.fl_str_mv |
2022-06-16 |
| dc.date.accessioned.fl_str_mv |
2023-12-07T22:51:50Z |
| dc.date.available.fl_str_mv |
2023-12-07T22:51:50Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/1843/61859 |
| dc.identifier.doi.pt_BR.fl_str_mv |
https://doi.org/10.1371/journal. pone.0269997 |
| dc.identifier.issn.pt_BR.fl_str_mv |
1932-6203 |
| dc.identifier.orcid.pt_BR.fl_str_mv |
https://orcid.org/0000-0003-0538-7403 |
| url |
https://doi.org/10.1371/journal. pone.0269997 http://hdl.handle.net/1843/61859 https://orcid.org/0000-0003-0538-7403 |
| identifier_str_mv |
1932-6203 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.relation.ispartof.pt_BR.fl_str_mv |
Plos One |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais |
| dc.publisher.initials.fl_str_mv |
UFMG |
| dc.publisher.country.fl_str_mv |
Brasil |
| dc.publisher.department.fl_str_mv |
HCL - HOSPITAL DAS CLINICAS MEDICINA - FACULDADE DE MEDICINA |
| publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFMG instname:Universidade Federal de Minas Gerais (UFMG) instacron:UFMG |
| instname_str |
Universidade Federal de Minas Gerais (UFMG) |
| instacron_str |
UFMG |
| institution |
UFMG |
| reponame_str |
Repositório Institucional da UFMG |
| collection |
Repositório Institucional da UFMG |
| bitstream.url.fl_str_mv |
https://repositorio.ufmg.br/bitstream/1843/61859/1/License.txt https://repositorio.ufmg.br/bitstream/1843/61859/2/Performance%20differences%20among%20commercially%20available%20antigen%20rapid%20tests%20for%20COVID-19%20in%20Brazil.pdf |
| bitstream.checksum.fl_str_mv |
fa505098d172de0bc8864fc1287ffe22 c5748642ac5f83cf6b04b0755c49b2ab |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG) |
| repository.mail.fl_str_mv |
|
| _version_ |
1803589456385540096 |